Literature DB >> 23179917

Snare coupling of the pre-pectoral pacing lead delivery catheter to the femoral transseptal apparatus for endocardial cardiac resynchronization therapy : mid-term results.

Mehul B Patel1, Seth J Worley.   

Abstract

AIMS: Limitations imposed by the coronary sinus venous anatomy triggered the transseptal approach for endocardial LV lead placement. The alignment of the interatrial septum (IAS) and its neighborhood anatomy does not favor transseptal puncture from the pre-pectoral area. Locating and advancing a pre-pectoral LV lead delivery catheter (PDC) through an opening created in the IAS via femoral transseptal puncture (FTP) is time consuming and technically difficult. We describe a method where the PDC is snare coupled to the femoral transseptal apparatus (FTA). When the FTA is advanced into the left atrium (LA) the coupled PDC follows.
METHODS: The catheter of a 25-mm loop snare kit is replaced with the PDC (SelectSite®). The snare loop is positioned in the right common iliac vein from the pre-pectoral access. The PDC is coupled to the FTA by advancing the transseptal apparatus through the open snare loop. After conventional FTP, the FTA is withdrawn back into the right atrium (RA) over an extra support wire positioned in the LA. The PDC with open snare loop is pulled over the FTA up to the RA. The PDC is advanced to close the snare loop on the extra support wire immediately distal to the tip of the dilator close to the puncture site. The PDC is deflected to align with the FTA. The snare coupled catheters are gently advanced across the IAS into the LA. The PDC is released from the FTA by advancing the snare and opening the loop; the snare is then removed from the PDC. The PDC is deflected and advanced into the left ventricle (LV). After positioning the 4.1 Fr lumen less LV lead, the PDC is sliced and removed.
RESULTS: The PDC snare coupled to the FTA was advanced into the LA in all five patients, however, access was lost during catheter manipulation in the one right-sided case. Endocardial LV lead was successfully positioned in all five patients.
CONCLUSION: Snare coupling the pre-pectoral SelectSite® catheter to the FTA is technically simple, reliable and a safe method for transseptal endocardial LV lead placement for left pre-pectoral implantation.

Entities:  

Mesh:

Year:  2012        PMID: 23179917     DOI: 10.1007/s10840-012-9734-x

Source DB:  PubMed          Journal:  J Interv Card Electrophysiol        ISSN: 1383-875X            Impact factor:   1.900


  20 in total

1.  Implantation techniques and chronic lead parameters of biventricular pacing dual-chamber defibrillators.

Authors:  Emile G Daoud; Steven J Kalbfleisch; John D Hummel; Raul Weiss; Ralph S Augustini; Steven B Duff; Georgia Polsinelli; John Castor; Tejas Meta
Journal:  J Cardiovasc Electrophysiol       Date:  2002-10

2.  Left ventricular endocardial lead placement using a modified transseptal approach.

Authors:  Sen Ji; David A Cesario; Charles D Swerdlow; Kalyanam Shivkumar
Journal:  J Cardiovasc Electrophysiol       Date:  2004-02

3.  Safety of transvenous cardiac resynchronization system implantation in patients with chronic heart failure: combined results of over 2,000 patients from a multicenter study program.

Authors:  Angel R León; William T Abraham; Anne B Curtis; James P Daubert; Westby G Fisher; John Gurley; David L Hayes; Randy Lieberman; Susan Petersen-Stejskal; Kevin Wheelan
Journal:  J Am Coll Cardiol       Date:  2005-12-20       Impact factor: 24.094

4.  Targeted left ventricular endocardial pacing using a steerable introducing guide catheter and active fixation pacing lead.

Authors:  John M Morgan; Paul A Scott; Nicholas G Turner; Arthur M Yue; Paul R Roberts
Journal:  Europace       Date:  2009-03-11       Impact factor: 5.214

5.  Endocardial biventricular pacing.

Authors:  P Jaïs; H Douard; D C Shah; S Barold; J L Barat; J Clémenty
Journal:  Pacing Clin Electrophysiol       Date:  1998-11       Impact factor: 1.976

6.  Yoked catheter positioning in transseptal endocardial left ventricular lead placement.

Authors:  Ernest W Lau
Journal:  Pacing Clin Electrophysiol       Date:  2011-03-21       Impact factor: 1.976

7.  Optimal left ventricular endocardial pacing sites for cardiac resynchronization therapy in patients with ischemic cardiomyopathy.

Authors:  David D Spragg; Jun Dong; Barry J Fetics; Robert Helm; Joseph E Marine; Alan Cheng; Charles A Henrikson; David A Kass; Ronald D Berger
Journal:  J Am Coll Cardiol       Date:  2010-08-31       Impact factor: 24.094

8.  Optimizing hemodynamics in heart failure patients by systematic screening of left ventricular pacing sites: the lateral left ventricular wall and the coronary sinus are rarely the best sites.

Authors:  Nicolas Derval; Paul Steendijk; Lorne J Gula; Antoine Deplagne; Julien Laborderie; Frederic Sacher; Sebastien Knecht; Matthew Wright; Isabelle Nault; Sylvain Ploux; Philippe Ritter; Pierre Bordachar; Stephane Lafitte; Patricia Réant; George J Klein; Sanjiv M Narayan; Stephane Garrigue; Mélèze Hocini; Michel Haissaguerre; Jacques Clementy; Pierre Jaïs
Journal:  J Am Coll Cardiol       Date:  2009-11-20       Impact factor: 24.094

9.  Transseptal endocardial left ventricular pacing: an alternative technique for coronary sinus lead placement in cardiac resynchronization therapy.

Authors:  Berry M van Gelder; Mike G Scheffer; Albert Meijer; Frank A Bracke
Journal:  Heart Rhythm       Date:  2006-11-29       Impact factor: 6.343

10.  Implantation of cardiac resynchronization therapy systems in the CARE-HF trial: procedural success rate and safety.

Authors:  D Gras; D Böcker; M Lunati; H J J Wellens; M Calvert; N Freemantle; R Gervais; L Kappenberger; L Tavazzi; E Erdmann; J G F Cleland; J-C Daubert
Journal:  Europace       Date:  2007-05-31       Impact factor: 5.214

View more
  1 in total

1.  Wire Transfer from the Femoral to Axillary Vein to Implant a Coronary Sinus Lead.

Authors:  Serkan Cay; Ozcan Ozeke; Firat Ozcan; Dursun Aras; Serkan Topaloglu
Journal:  Acta Cardiol Sin       Date:  2022-05       Impact factor: 1.800

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.